Neuromyelitis optica spectrum disorder represents a severe autoimmune astrocytopathy that targets the central nervous system. Autoantibodies against aquaporin-4 initiate complement-mediated destruction of astrocytic end-feet, leading to rapid blood-brain barrier breakdown and myeloid cell infiltration. Recent discoveries regarding ISG15 in NMOSD reveal an essential molecular mechanism connecting peripheral immune recruitment to sustained neuroinflammation. Interferon-stimulated gene 15 acts as a pivotal cytokine and intracellular modifier that amplifies innate inflammatory signaling. Consequently, understanding this neuroinflammatory pathway provides clinicians and neuroimmunology specialists with crucial insights into disease progression, clinical severity, and potential therapeutic intervention points.

Aquaporin-4 Autoimmunity and Blood-Brain Barrier Breakdown

Neuromyelitis optica spectrum disorder primarily involves pathogenic immunoglobulin G autoantibodies directed against aquaporin-4 water channels on astrocytic foot processes. When circulating autoantibodies cross the compromised blood-brain barrier, they bind selectively to astrocytic surfaces and trigger classical complement activation. Consequently, astrocytes undergo complement-dependent cytotoxicity and lytic necrosis, which rapidly undermines neurovascular structural integrity. Astrocytic detachment disrupts tight junction proteins between cerebral vascular endothelial cells, thereby escalating vascular permeability. In addition, this vascular barrier failure invites aggressive peripheral immune cells into vulnerable central nervous system compartments. Granulocytes, lymphocytes, and circulating monocytes rapidly flood spinal cord and optic nerve tissues. Furthermore, reactive astrocytes release localized chemokines that intensify myeloid recruitment. Therefore, early blood-brain barrier disruption represents a decisive turning point in disease progression. Infiltrating leukocytes encounter resident parenchymal cells, creating a fertile microenvironment for widespread inflammatory cascades. As a result, acute structural damage quickly transforms into a profound, self-perpetuating neuroinflammatory episode that threatens visual acuity and spinal cord integrity.

The Mechanistic Role of ISG15 in NMOSD Pathogenesis

Interferon-stimulated gene 15 represents a distinct ubiquitin-like protein that responds rapidly to type I interferon signaling. In healthy neurological tissues, cells maintain minimal basal ISG15 concentrations to avoid unwanted inflammatory cascades. However, clinical evaluations show marked ISG15 elevations across peripheral blood mononuclear cells, serum, and cerebrospinal fluid during flares. Specifically, peripheral CD14-positive monocytes display marked transcriptional expansion of interferon and pattern recognition receptor pathways. Inside cells, ISG15 exists as both unconjugated free protein and covalent substrate conjugates via ISGylation. Furthermore, combined lipopolysaccharide and interferon-beta stimulation dramatically elevates both free and conjugated ISG15 in macrophages. Moreover, functional genetic manipulation proves that ISG15 directly controls inflammatory behavior. Silencing ISG15 significantly reduces myeloid cytokine release and migratory competence. Conversely, ectopic ISG15 overexpression markedly accelerates inflammatory cytokine transcription. Consequently, elevated ISG15 in NMOSD serves not merely as an idle bystander of interferon activation, but as an indispensable upstream driver of myeloid cell toxicity.

RIG-I-Like Receptor Signaling in Myeloid Hyperactivation

Retinoic acid-inducible gene I and melanoma differentiation-associated protein 5 represent pivotal cytosolic pattern recognition receptors within the innate immune apparatus. While evolutionary mechanisms developed these sensors to detect viral ribonucleic acids, sterile neuroinflammatory conditions often hijack this delicate machinery. Recent molecular investigations demonstrate that ISG15 directly modulates the transcription and protein abundance of RIG-I, MDA5, and the laboratory of genetics and physiology 2 protein. Furthermore, co-immunoprecipitation assays definitively prove that ISG15 physically associates with the RIG-I receptor complex in activated myeloid cells. This structural binding stabilizes receptor complexes and promotes sustained downstream signal transduction. In experimental rescue protocols, overexpression of RIG-I successfully restores inflammatory gene signatures following ISG15 knockdown, confirming their close functional dependency. Therefore, the ISG15-RLR signaling cascade functions as an autocrine amplifier of innate inflammatory programs. Rather than resolving following initial immune activation, macrophages and monocytes experience persistent receptor stimulation. Consequently, this persistent activation perpetuates transcription of downstream interferon-stimulated genes, chemokines, and toxic intermediaries, which sustain unremitting neurodestructive responses within spinal and optic neural tracts.

Macrophage-Microglia Crosstalk Across the Neurovascular Unit

The interplay between peripheral infiltrating macrophages and resident central nervous system microglia dictates the trajectory of tissue injury. After vascular integrity fails, infiltrating peripheral macrophages navigate the perivascular space and directly engage resident parenchymal microglia. To characterize this bidirectional interaction, researchers utilized non-contact Transwell coculture systems. These sophisticated cellular experiments confirmed that macrophage-derived ISG15 directly commands microglial polarization states. Specifically, macrophages overexpressing ISG15 readily induce resident microglia to adopt a neurotoxic M1 phenotype characterized by high inducible nitric oxide synthase expression. Conversely, suppressing ISG15 expression within macrophages effectively prevents this noxious shift, instead preserving neuroprotective M2 microglial markers such as arginase-1. Furthermore, secreted extracellular ISG15 functions as a potent paracrine mediator that diffuses across extracellular spaces to trigger microglial activation independently of cell contact. In vivo passive-transfer animal models validate these findings. Concurrently with severe barrier leakage, diseased spinal tissues demonstrate striking accumulations of ISG15-rich infiltrating macrophages closely juxtaposed with reactive microglia. Thus, the ISG15-RLR axis coordinates a catastrophic intercellular dialogue that amplifies focal tissue damage.

Translational Insights and Diagnostic Biomarkers

These molecular discoveries provide profound clinical relevance for practicing neurologists and diagnostic specialists managing neuroinflammatory disorders. Differentiating neuromyelitis optica spectrum disorder from multiple sclerosis and myelin oligodendrocyte glycoprotein antibody-associated disease often presents substantial diagnostic challenges. Because peripheral CD14 monocytes and cerebrospinal fluid display robust ISG15-high interferon signatures during acute flares, ISG15 quantification may serve as an informative disease activity biomarker. In addition, cerebrospinal fluid levels of myeloid activation markers closely correlate with Expanded Disability Status Scale scores during acute exacerbations. Therefore, tracking ISG15 concentrations alongside conventional aquaporin-4 antibody titers could help clinicians evaluate subclinical neuroinflammation and blood-brain barrier permeability. Moreover, measuring downstream RIG-I and MDA5 expression patterns offers a novel window into ongoing myeloid activation within individual patients. Incorporating these molecular parameters into routine diagnostic panels could refine prognostic assessments and help identify individuals at heightened risk for devastating relapses. Consequently, validating these biomarkers in diverse patient cohorts represents an essential step toward standardizing individualized risk profiles and monitoring biological treatment responses in clinical practice.

Emerging Therapeutic Strategies Beyond B-Cell Depletion

Current standard therapies for neuromyelitis optica spectrum disorder primarily focus on preventing relapses through targeted monoclonal antibodies. Modern agents that deplete CD20-positive B cells, inhibit interleukin-6 receptor signaling, or block the C5 complement component have revolutionized patient outcomes. Nevertheless, substantial clinical challenges remain because many individuals continue to experience residual disability, subclinical neurodegeneration, and refractory myeloid inflammation. Intervening in the ISG15-RLR axis emerges as a highly promising adjunct therapeutic avenue to address these unmet medical needs. Specifically, small-molecule inhibitors targeting the enzymes that govern ISGylation could suppress pathologic protein conjugation without ablating essential adaptive immunity. Furthermore, pharmacological antagonists of RIG-I or MDA5 receptor oligomerization might extinguish damaging macrophage-microglia crosstalk before extensive parenchymal destruction occurs. Combining conventional complement or B-cell blockade with targeted myeloid signaling inhibitors could provide comprehensive dual-compartment protection across the blood-brain barrier. Consequently, advancing research into selective ISG15 pathway modulators holds substantial promise for halting progressive axonal loss and improving long-term functional independence in affected patients.

Frequently Asked Questions

How does ISG15 contribute to neuroinflammation in NMOSD?

ISG15 functions as a vital molecular amplifier in neuromyelitis optica spectrum disorder. In both free and conjugated forms, it intensifies RIG-I and MDA5 receptor expression within monocytes, macrophages, and microglia. Consequently, this persistent activation enhances proinflammatory cytokine production, promotes microglial M1 polarization, and accelerates blood-brain barrier permeability. Through these synchronized actions, elevated ISG15 bridges peripheral myeloid cell recruitment with destructive central nervous system inflammation during acute autoimmune flares.

What role does the RIG-I/MDA5 pathway play in astrocytic disease?

The RIG-I-like receptor pathway traditionally senses viral RNA, yet it serves as an indispensable driver of sterile innate inflammation in astrocytopathy. When extracellular and intracellular ISG15 levels rise following astrocytic damage, RIG-I and MDA5 associate physically with ISG15. This interaction directly activates downstream antiviral-like signaling cascades without an active viral infection. Consequently, myeloid cells produce elevated interferon-stimulated genes, chemokines, and reactive oxygen species that accelerate oligodendrocyte destruction and profound myelin injury.

Can ISG15 serve as a biomarker or therapeutic target in NMOSD?

Yes, clinical data show marked ISG15 elevations in peripheral blood monocytes, serum, and cerebrospinal fluid during active disease. Because current therapies focus largely on B-cell depletion and complement inhibition, refractory neuroinflammation frequently persists. Targeting the ISG15-RLR signaling axis offers a promising adjunct strategy. Selectively blocking ISG15 conjugation or silencing RIG-I-like receptors may attenuate damaging macrophage-microglia crosstalk, thereby protecting the blood-brain barrier and preserving neurological function during attacks.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Niu Y et al. Elevated ISG15 reinforces RIG-I/MDA5-linked macrophage-microglia crosstalk during blood-brain barrier disruption in neuromyelitis optica spectrum disorder. Int Immunopharmacol. 2026 Sep 19. doi: undefined. PMID: 42763248.
2. Clarkson BD et al. ISGylation is induced in neurons by demyelination driving ISG15-dependent microglial activation. J Neuroinflammation. 2022;19(1):255.
3. Liu Y et al. Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders. Brain Behav. 2022;12(12):e2798.